Latest Conference Articles

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.

Presented at AAO 2023, a new analysis indicates racial and ethnic minoritized individuals may have a higher likelihood of neovascular glaucoma.

Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.

Lassailly discusses the role of bariatric surgery versus weight-loss treatments like semaglutide for patients with MASH.

Cynthia Levy, MD, professor of medicine at the University of Miami, provided further insight into unmet needs in PBC, the use of OCA-bezafibrate in PBC, and the significance of results from a pair of phase 2 studies presented at The Liver Meeting.

At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.

After a 12-week gap, 5% of patients returned to pegloticase and responded well.

Most ophthalmology teaching faculty noted their lack of awareness about available resources or training as a barrier, rather than a lack of time, perceived benefit, or funding.

Chari Cohen, DrPH, MPH, discusses the current landscape of hepatitis B management and areas she sees room for development.

At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.

At AAO 2023, Korobelnik provides insight into the efficacy and safety of aflibercept 8 mg in patients with nAMD observed over 2 years of the PULSAR study.

Sustained remission was observed in more patients receiving rituximab and concomitant avacopan compared with those treated with concomitant prednisone.

At AAO 2023, Kay shares insight into the topline results of the TEASE-1 study investigating the effect of gildeuretinol (ALK-001) on the inherited retinal disease.

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.

A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.

In this late-breaking research shown at ACR 2023, TLC599 injection led to benefits in patients with a single injection and further benefits with a second.

The study revealed that patients meeting fibromyalgia criteria or displaying fibromyalgia-like symptoms were less likely to meet standardized response criteria with biologic therapy.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.

Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.

The study author discusses the impact of findings showing MASH resolution without worsening fibrosis is a surrogate endpoint for 15-year bariatric surgery survival.